Table 1—

Anthropometric data, urine catecholamines, blood pressure, antihypertensive drugs, and prevalence of cardiovascular disease (CVD) in subjects with obstructive sleep apnoea (OSA) compared to subjects without OSA (non‐OSA)

Subjects n7244
Age yrs58.9±9.763.8±8.8**
BMI kg·m−226.7±3.729.2±4.8**
Overnight urine volume555±304634±343
U‐norepinephrine µmol·mol−118.2±8.620.2±6.8
U‐normetanephrine µmol·mol−1141±45182±57***
U‐MHMA mmol·mol−11.7±0.71.7±0.5
U‐metanephrine µmol·mol−161±2870±28*
U‐mettyramine µmol·mol−191±6194±31
Systolic blood pressure mmHg148±17.6153±20.4
Diastolic blood pressure mmHg91±9.492±12.5
Users of β‐blockers40 (55.6)19 (43.2)
Users of ACE inhibitors27 (37.5)16 (36.4)
Users of calcium channel antagonists24 (33.3)15 (34.1)
CVD10 (13.9)16 (36.4)**
  • Data are presented as mean±sd or n %

  • Non‐OSA: subjects without obstructive sleep apnoea

  • OSA: subjects with obstructive sleep apnoea

  • BMI: body mass index

  • WHR: wais-to-hip ratio

  • U: urinary

  • MHMA: methoxy-hydroxy-mandelic acid

  • ACE: angiotensin-converting enzyme

  • CVD: cardiovascular disease

  • Non‐OSA was defined as apnoea-hypopnoea index<10·h−1 of sleep and OSA as apnoea-hypopnoea index≥10·h−1 of sleep

  • Catecholamines were measured per mol of creatinine

  • *: p<0.05

  • **: p<0.01

  • ***: p<0.001